BofA lowered the firm’s price target on Charles River (CRL) to $195 from $210 and keeps a Neutral rating on the shares. The firm updated its forecasts to incorporate the initial FY25 outlook provided by Charles River on January 14, but notes that its updated model does not account into the possible suspension of non-human primates from Cambodia, which would adversely impact the company’s Discovery and Safety Assessment segment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River downgraded to Market Perform from Outperform at William Blair
- Salesforce upgraded, Southwest downgraded: Wall Street’s top analyst calls
- Charles River downgraded to Neutral from Buy at UBS
- Charles River and Akron Bio team on CSS integration for cell therapy
- Charles River Labs Discusses 2025 Financial Outlook